The evolving role of HIV counseling and testing in resource-limited settings: HIV prevention and linkage to expanding HIV care access

Current Infectious Disease Reports

Volumn 7, Issue 2, 2005, Pages 154-158

  Liechty, Cheryl A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; FLUCONAZOLE;

BEHAVIOR MODIFICATION; COST EFFECTIVENESS ANALYSIS; FEASIBILITY STUDY; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE NEED; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MEDICAL RESEARCH; PALLIATIVE THERAPY; PATIENT ATTITUDE; PATIENT COUNSELING; PREVENTIVE HEALTH SERVICE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SCREENING; SERODIAGNOSIS;

EID: 17044402211     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0076-z     Document Type: Review

References (50)

1. Merson MH, Dayton JM, O'Reilly K: Effectiveness of HIV prevention interventions in developing countries. AIDS 2000, 14(Suppl 2):68-84.
2. Mellins CA, Ehrhardt AA: Families affected by pediatric acquired immunodeficiency syndrome: sources of stress and coping. J Dev Behav Pediatr 1994, 15:S54-S60
3. Chesney MA, Folkman S: Psychological impact of HIV disease and implications for intervention. Psychiatr Clin North Am 1994, 17:163-182.
4. Kelly JA, Murphy DA, Bahr GR, et al.: Outcome of cognitive-behavioral and support group brief therapies for depressed, HIV-infected persons. Am J Psychiatry 1993,150:1679-1686.
5. Grinstead OA, van der Straten A: Counselor's perspectives on the experience of providing HIV counseling on Kenya and Tanzania: The Voluntary HIV1 Counseling and Testing Efficacy Study. AIDS Care, 2000, 12:625-642.
6. Sweat M, Gregorich S, Sangiwa G, et al.: Cost effectiveness of voluntary HIV1 counseling and testing in reducing sexual transmission of HIV1 in Kenya and Tanzania. Lancet 2000, 8: 13-121.
7. Balmer D, Kikuho F: Characteristics of individuals and couples seeking HIV1 prevention services in Nairobi, Kenya: the voluntary HIV1 counseling and testing efficacy study. AIDS Behav 2000, 4:15-23.
8. The impact of voluntary counseling and testing - a global review of the benefits and challenges. UNAIDS Best Practice Collection. Geneva, Switzerland: UNAIDS, 2001.
9. Alwano-Edyegu MG, Roels TH, Mokomane M, et al.: The effect of introducing antiretroviral therapy in the public setting on utilization of voluntary counseling and testing (VCT) services in Botswana, 2001-2003. Paper presented at the XV International AIDS Conference. Bangkok, Thailand, July 12, 2004.
10. Treating 3 million by 2005: Making it Happen, the World Health Organization (WHO) Strategy. Geneva, Switzerland: World Health Organization; 2003.
11. Were W, Mermin J, Bunnel R, et al.: Home-based model for HIV voluntary counselling and testing. Lancet 2003, 361: 569.
12. Molosiwa R, Mokomane M, Alwano-Edyegu MG, et al.: VCT on wheels: increasing access to voluntary HIV counseling and testing (VCT) services through use of mobile caravans Botswana. Paper presented at the XV International AIDS Conference. Bangkok, Thailand; July 14, 2004.
13. Centers for Disease Control and Prevention: Revised guidelines for HIV couseling, testing, and referral. MMWR Recomm Rep 2001, 9:1-57.
14. Downing RG, Otten RA, Marum E, et al.: Optimizing the delivery of HIV counseling and testing services: the Uganda experience using rapid HIV antibody test algorithms. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18:384-388.
15. The Voluntary HIV1 Counseling and Testing Efficacy Study Group: Efficacy of voluntary HIV1 counseling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. Lancet 2000, 356:103-112.
16. Sweat MD, Denison JA: Reducing HIV incidence in developing countries with structural and environmental interventions. AIDS 1995, 9(Suppl A:)251-257.
17. Zachariah R, Spielmann MP, Harries AD, et al.: Voluntary counseling, HIV testing and sexual behaviour among patients with tuberculosis in a rural district of Malawi. Int J Tuberc Lung Dis 2003, 7:65-71.
18. Grinstead OA, Gregorich SE, Choi KH, et al.: Positive and negative life events after counseling and testing: the voluntary HIV1 counseling and testing efficacy study. AIDS 2001, 15:1045-1052.
19. Sweat M, Gregorich S, Sangiwa G, et al.: Cost-effectiveness of voluntary HIV1 counselling and testing in reducing sexual transmission of HIV in Kenya and Tanzania. Lancet 2000, 356:113-121.
20. Marseille E, Hofmann PB, Kahn JG: HIV prevention before HAART in subSaharan Africa. Lancet 2002, 359:1851-1856.
21. Muller O, Barugahare L, Scwartlander B, et al.: HIV prevalence, attitudes, and behaviour in clients of a confidential HIV testing and counseling centre in Uganda. AIDS 1992, 6: 69-874.
22. Mugerwa RD, Marun LH, Serwadda D: Human immunodeficiency virus and AIDS in Uganda. East Afr Med J 1996, 73:20-26.
23. Kassler WJ, Alwano-Edyegu MG, Marum E, et al.: Rapid HIV testing with same-day results: a field trial in Uganda. Int J STD AIDS 1998, 9:134-138.
24. Kipp W, Kabagambe G, Konde-Lule J: Low impact of a community-wide HIV testing and counseling program on sexual behavior in rural Uganda. AIDS Educ Prev 2001, 13:279-289.
25. Pool R, Nyanzi S, Whitworth JA: Attitudes to voluntary counseling and testing for HIV among pregnant women in rural south-west Uganda. AIDS Care 2001, 13:605-615.
26. Nyblade LC, Menken J, Wawer MJ, et al.: Population-based HIV testing and counseling in rural Uganda: participation and risk characteristics. J Acquir Immune Defic Syndr 2001, 28:463-470.
27. Worthington H: Where voluntary testing has produced results. AIDS Anal Afr 1997, 7:3.
28. Kamali A, Carpenter LM, Whitworth JA, et al.: Seven-year trends in HIV1 infection rates, and changes in sexual behaviour, among adults in rural Uganda. AIDS 2000, 14: 27-434.
29. Alwano-Edyegu MG: Knowledge is power: voluntary counseling and testing in Uganda. UNAIDS; June 1999.
30. De Cock KM, Marum E, Mbori-Ngacha D: A serostatus-based approach to HIV/AIDS prevention and care in Africa. Lancet 2003, 362:1847-1849.
31. De Cock KM: Screening for tuberculosis and HIV in resource-poor countries. Lancet 1995, 345:873-874.
32. Palmer DL, Mason PR, Pasi C, et al.: Value of mandatory testing for human immunodeficiency virus in a subSaharan hospital population. Clin Infect Dis 2000, 31:1258-1265.
33. Kwesigabo G, Killewo JZ Sandstrom A, et al.: Prevalence of HIV infection among hospital patients in north west Tanzania. AIDS Care 1999, 11:87-93.
34. Anglaret X, Chene G, Attia A, et al.: Early chemophylaxis with trimethoprim-sulphamethoxazole for HIV1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999, 353:1463-1468.
35. Wiktor SZ, Sassan-Morokro M, Grant AD, et al.: Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999, 353:1469-1475.
36. Whalen CC, Johnson JL, Okwera A, et al.: A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus, Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997, 337:801-808.
37. Provisional World Health Organization/UNAIDS Secretariat Recommendations on the Use of Cotrimoxazole Prohylaxis in Adults and Children Living with HIV/AIDS in Africa. Geneva, Switzerland: World Health Organization; 2000.
38. Policy Statement on Preventive Therapy Aganist Tuberculosis in People Living with HIV. Geneva, Switzerland: World Health Organization; 2001.
39. Pfizer to offer Diflucan free to patients with AIDS in least-developed countries. http://www.aegis.com/news/wsj/2001/WJ010617.html. Accessed June 6, 2001.
40. Bureau for Global Health, United States Agency for International Development: HIV/AIDS Country Profile: Uganda. 2003.
41. Ramsay S: Leading the way in African home-based palliative care. Lancet 2003, 362:1812-1813.
42. Kaleeba N, Kalibala S, Kaseje M, et al.: Participatory evaluation of counseling, medical and social services of The AIDS Support Organization (TASO) in Uganda. AIDS Care 1997, 9:13-26.
43. Kalibala S, Kaleeba N: AIDS and community-based care in Uganda: the AIDS support organization, TASO. AIDS Care 1989, 1:173-175.
44. Scaling up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2003.
45. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921-929.
46. Cohen MS, Hosseinipour M, Kashuba A, et al.: Use of antiretroviral drugs to prevent sexual transmission of HIV. Curr Clin Top Infect Dis 2002, 22:214-251.
47. Hosseinipour M, Cohen MS, Vernazza PL, et al.: Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin Infect Dis 2002, 34: 391-1395.
48. Kashuba AD, Dyer JR, Kramer LM, et al.: Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999, 43:1817-1826.
49. Chakraborty H, Sen PK, Helms RW, et al.: Viral burden in genital secretions determines male-to-female sexual transmission of HIV1: a probabilistic empiric models. AIDS 2001, 15:621-627.
50. Wanyenze R, Liechty CA, Bangsberg DR, et al.: HIV risk behavior and acceptability of HIV counseling and testing in an urban teaching and national referral hospital in Kampala, Uganda. Paper presented at the XV International AIDS Conference. Bangkok, Thailand, July 14, 2004.